Ken Griffin Ovid Therapeutics Inc. Call Options Transaction History

Citadel Advisors LLC

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2025 May 15, 2025	SELL	$0.31 - $0.96 $217 - $672	-700 Reduced 29.17%	1,700 $0
Q4 2024 Feb 14, 2025	SELL	$0.93 - $1.36 $32,550 - $47,600	-35,000 Reduced 93.58%	2,400 $2,000
Q3 2024 Nov 14, 2024	BUY	$0.75 - $1.3 $20,325 - $35,230	27,100 Added 263.11%	37,400 $44,000
Q2 2024 Aug 14, 2024	BUY	$0.7 - $3.34 $3,080 - $14,696	4,400 Added 74.58%	10,300 $7,000
Q1 2024 May 15, 2024	BUY	$2.72 - $4.04 $10,064 - $14,948	3,700 Added 168.18%	5,900 $17,000
Q4 2023 Feb 14, 2024	BUY	$2.98 - $3.78 $6,556 - $8,316	2,200 New	2,200 $7,000
Q2 2023 Aug 14, 2023	SELL	$2.53 - $3.89 $3,541 - $5,446	-1,400 Reduced 12.73%	9,600 $31,000
Q1 2023 May 15, 2023	BUY	$1.88 - $2.85 $3,384 - $5,130	1,800 Added 19.57%	11,000 $28,000
Q4 2022 Feb 14, 2023	SELL	$1.43 - $1.89 $20,020 - $26,460	-14,000 Reduced 60.34%	9,200 $17,000
Q3 2022 Nov 14, 2022	SELL	$1.84 - $2.26 $1,472 - $1,807	-800 Reduced 3.33%	23,200 $43,000

39.1M

1.7K

100

Ticker OVID
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,419,400
Market Cap $38.7M
Description
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment o...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.